Logo image of RGNX

REGENXBIO INC (RGNX) Stock Fundamental Analysis

NASDAQ:RGNX - Nasdaq - US75901B1070 - Common Stock - Currency: USD

7.27  -0.09 (-1.22%)

After market: 7.27 0 (0%)

Fundamental Rating

3

Taking everything into account, RGNX scores 3 out of 10 in our fundamental rating. RGNX was compared to 571 industry peers in the Biotechnology industry. The financial health of RGNX is average, but there are quite some concerns on its profitability. RGNX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RGNX had negative earnings in the past year.
RGNX had a negative operating cash flow in the past year.
In the past 5 years RGNX reported 4 times negative net income.
In the past 5 years RGNX reported 4 times negative operating cash flow.
RGNX Yearly Net Income VS EBIT VS OCF VS FCFRGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

1.2 Ratios

RGNX has a Return On Assets (-46.00%) which is comparable to the rest of the industry.
RGNX has a Return On Equity of -79.23%. This is comparable to the rest of the industry: RGNX outperforms 52.40% of its industry peers.
Industry RankSector Rank
ROA -46%
ROE -79.23%
ROIC N/A
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A
RGNX Yearly ROA, ROE, ROICRGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

RGNX has a Gross Margin of 54.36%. This is in the better half of the industry: RGNX outperforms 77.98% of its industry peers.
In the last couple of years the Gross Margin of RGNX has declined.
The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%
RGNX Yearly Profit, Operating, Gross MarginsRGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RGNX has been increased compared to 1 year ago.
The number of shares outstanding for RGNX has been increased compared to 5 years ago.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RGNX Yearly Shares OutstandingRGNX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
RGNX Yearly Total Debt VS Total AssetsRGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -2.27, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of RGNX (-2.27) is comparable to the rest of the industry.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.27
ROIC/WACCN/A
WACC9.44%
RGNX Yearly LT Debt VS Equity VS FCFRGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.05 indicates that RGNX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.05, RGNX is doing worse than 64.48% of the companies in the same industry.
A Quick Ratio of 3.05 indicates that RGNX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.05, RGNX is not doing good in the industry: 62.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 3.05
RGNX Yearly Current Assets VS Current LiabilitesRGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.72%, which is quite good.
Looking at the last year, RGNX shows a very negative growth in Revenue. The Revenue has decreased by -15.08% in the last year.
The Revenue for RGNX have been decreasing by -16.21% on average. This is quite bad
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.02%
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Sales Q2Q%-16.31%

3.2 Future

The Earnings Per Share is expected to grow by 15.83% on average over the next years. This is quite good.
Based on estimates for the next years, RGNX will show a very strong growth in Revenue. The Revenue will grow by 41.61% on average per year.
EPS Next Y18.74%
EPS Next 2Y33.79%
EPS Next 3Y8.74%
EPS Next 5Y15.83%
Revenue Next Year-10.93%
Revenue Next 2Y77.73%
Revenue Next 3Y28.02%
Revenue Next 5Y41.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RGNX Yearly Revenue VS EstimatesRGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
RGNX Yearly EPS VS EstimatesRGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RGNX Price Earnings VS Forward Price EarningsRGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RGNX Per share dataRGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.79%
EPS Next 3Y8.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RGNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

REGENXBIO INC

NASDAQ:RGNX (2/21/2025, 8:00:01 PM)

After market: 7.27 0 (0%)

7.27

-0.09 (-1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners89.3%
Inst Owner Change-2.14%
Ins Owners7.33%
Ins Owner Change3.45%
Market Cap360.23M
Analysts85.88
Price Target33.49 (360.66%)
Short Float %14.06%
Short Ratio4.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.03%
Min EPS beat(2)-2.21%
Max EPS beat(2)20.28%
EPS beat(4)1
Avg EPS beat(4)1.04%
Min EPS beat(4)-10.34%
Max EPS beat(4)20.28%
EPS beat(8)3
Avg EPS beat(8)-1.46%
EPS beat(12)4
Avg EPS beat(12)-2.09%
EPS beat(16)5
Avg EPS beat(16)-15.05%
Revenue beat(2)1
Avg Revenue beat(2)-2.14%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)0.57%
Revenue beat(4)1
Avg Revenue beat(4)-18.78%
Min Revenue beat(4)-35.95%
Max Revenue beat(4)0.57%
Revenue beat(8)2
Avg Revenue beat(8)-20.84%
Revenue beat(12)4
Avg Revenue beat(12)-12.06%
Revenue beat(16)4
Avg Revenue beat(16)-17.73%
PT rev (1m)-3.38%
PT rev (3m)-4.52%
EPS NQ rev (1m)-2.95%
EPS NQ rev (3m)4.29%
EPS NY rev (1m)-0.21%
EPS NY rev (3m)-1.76%
Revenue NQ rev (1m)-0.37%
Revenue NQ rev (3m)-0.37%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.27
P/FCF N/A
P/OCF N/A
P/B 1.2
P/tB 1.2
EV/EBITDA N/A
EPS(TTM)-4.98
EYN/A
EPS(NY)-1.27
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.68
OCFYN/A
SpS1.7
BVpS6.08
TBVpS6.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46%
ROE -79.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.36%
FCFM N/A
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.24%
Cap/Sales 2.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.05
Quick Ratio 3.05
Altman-Z -2.27
F-Score4
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)390.86%
Cap/Depr(5y)331.06%
Cap/Sales(3y)18.73%
Cap/Sales(5y)21.36%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.02%
EPS Next Y18.74%
EPS Next 2Y33.79%
EPS Next 3Y8.74%
EPS Next 5Y15.83%
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Sales Q2Q%-16.31%
Revenue Next Year-10.93%
Revenue Next 2Y77.73%
Revenue Next 3Y28.02%
Revenue Next 5Y41.61%
EBIT growth 1Y6.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.52%
EBIT Next 3Y17.06%
EBIT Next 5Y15.81%
FCF growth 1Y-238.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-205.14%
OCF growth 3YN/A
OCF growth 5YN/A